nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—CYP1B1—ovarian cancer	0.228	0.777	CbGaD
Dasatinib—ABCB1—ovarian cancer	0.0654	0.223	CbGaD
Dasatinib—CYP1B1—Paclitaxel—ovarian cancer	0.0337	0.148	CbGbCtD
Dasatinib—ABCG2—Topotecan—ovarian cancer	0.0324	0.142	CbGbCtD
Dasatinib—CYP1B1—Docetaxel—ovarian cancer	0.0244	0.107	CbGbCtD
Dasatinib—CYP1B1—Doxorubicin—ovarian cancer	0.0182	0.0797	CbGbCtD
Dasatinib—ABCG2—Paclitaxel—ovarian cancer	0.016	0.0703	CbGbCtD
Dasatinib—ABCG2—Carboplatin—ovarian cancer	0.0151	0.0662	CbGbCtD
Dasatinib—ABCB1—Topotecan—ovarian cancer	0.0117	0.0512	CbGbCtD
Dasatinib—ABCG2—Docetaxel—ovarian cancer	0.0116	0.0508	CbGbCtD
Dasatinib—CYP3A5—Paclitaxel—ovarian cancer	0.00888	0.0389	CbGbCtD
Dasatinib—ABCG2—Doxorubicin—ovarian cancer	0.00864	0.0379	CbGbCtD
Dasatinib—ABCB1—Vinorelbine—ovarian cancer	0.00822	0.0361	CbGbCtD
Dasatinib—CYP3A4—Topotecan—ovarian cancer	0.00699	0.0307	CbGbCtD
Dasatinib—CYP3A5—Docetaxel—ovarian cancer	0.00642	0.0282	CbGbCtD
Dasatinib—ABCB1—Paclitaxel—ovarian cancer	0.00578	0.0253	CbGbCtD
Dasatinib—CYP3A4—Vinorelbine—ovarian cancer	0.00493	0.0216	CbGbCtD
Dasatinib—ABCB1—Docetaxel—ovarian cancer	0.00418	0.0183	CbGbCtD
Dasatinib—CYP3A4—Paclitaxel—ovarian cancer	0.00346	0.0152	CbGbCtD
Dasatinib—ABCB1—Doxorubicin—ovarian cancer	0.00311	0.0137	CbGbCtD
Dasatinib—CYP3A4—Docetaxel—ovarian cancer	0.0025	0.011	CbGbCtD
Dasatinib—EPHB2—Irinotecan—Topotecan—ovarian cancer	0.00192	0.54	CbGdCrCtD
Dasatinib—CYP3A4—Doxorubicin—ovarian cancer	0.00187	0.00818	CbGbCtD
Dasatinib—ERBB3—Vinblastine—Vinorelbine—ovarian cancer	0.000302	0.085	CbGdCrCtD
Dasatinib—EPHB6—decidua—ovarian cancer	0.000272	0.00212	CbGeAlD
Dasatinib—PDGFRB—myometrium—ovarian cancer	0.000271	0.00212	CbGeAlD
Dasatinib—STK35—vagina—ovarian cancer	0.000271	0.00212	CbGeAlD
Dasatinib—CSK—female gonad—ovarian cancer	0.000271	0.00212	CbGeAlD
Dasatinib—SIK1—female reproductive system—ovarian cancer	0.00027	0.00211	CbGeAlD
Dasatinib—MAP3K3—endometrium—ovarian cancer	0.00027	0.00211	CbGeAlD
Dasatinib—MAP4K5—endometrium—ovarian cancer	0.00027	0.00211	CbGeAlD
Dasatinib—CSK—vagina—ovarian cancer	0.00027	0.00211	CbGeAlD
Dasatinib—HCK—female gonad—ovarian cancer	0.000268	0.00209	CbGeAlD
Dasatinib—SRC—epithelium—ovarian cancer	0.000268	0.00209	CbGeAlD
Dasatinib—EPHA4—female reproductive system—ovarian cancer	0.000268	0.00209	CbGeAlD
Dasatinib—KIT—embryo—ovarian cancer	0.000267	0.00209	CbGeAlD
Dasatinib—HCK—vagina—ovarian cancer	0.000266	0.00208	CbGeAlD
Dasatinib—ABL2—female gonad—ovarian cancer	0.000266	0.00208	CbGeAlD
Dasatinib—SRC—uterine cervix—ovarian cancer	0.000265	0.00207	CbGeAlD
Dasatinib—ERBB3—female reproductive system—ovarian cancer	0.000265	0.00207	CbGeAlD
Dasatinib—ABL2—vagina—ovarian cancer	0.000265	0.00207	CbGeAlD
Dasatinib—YES1—decidua—ovarian cancer	0.000263	0.00205	CbGeAlD
Dasatinib—TESK1—testis—ovarian cancer	0.000263	0.00205	CbGeAlD
Dasatinib—MAP3K2—female reproductive system—ovarian cancer	0.000262	0.00205	CbGeAlD
Dasatinib—RIPK2—bone marrow—ovarian cancer	0.000261	0.00204	CbGeAlD
Dasatinib—PDGFRB—embryo—ovarian cancer	0.000261	0.00204	CbGeAlD
Dasatinib—EPHB4—uterus—ovarian cancer	0.00026	0.00203	CbGeAlD
Dasatinib—JAK2—gonad—ovarian cancer	0.00026	0.00203	CbGeAlD
Dasatinib—EPHB3—testis—ovarian cancer	0.000258	0.00202	CbGeAlD
Dasatinib—STK36—testis—ovarian cancer	0.000258	0.00202	CbGeAlD
Dasatinib—EPHB6—endometrium—ovarian cancer	0.000258	0.00202	CbGeAlD
Dasatinib—PDGFRA—decidua—ovarian cancer	0.000258	0.00201	CbGeAlD
Dasatinib—STAT5B—lymph node—ovarian cancer	0.000258	0.00201	CbGeAlD
Dasatinib—SIK1—bone marrow—ovarian cancer	0.000255	0.00199	CbGeAlD
Dasatinib—FYN—uterus—ovarian cancer	0.000255	0.00199	CbGeAlD
Dasatinib—SRC—decidua—ovarian cancer	0.000253	0.00198	CbGeAlD
Dasatinib—RIPK2—female gonad—ovarian cancer	0.000252	0.00197	CbGeAlD
Dasatinib—MAP3K3—gonad—ovarian cancer	0.000251	0.00196	CbGeAlD
Dasatinib—MAP4K5—gonad—ovarian cancer	0.000251	0.00196	CbGeAlD
Dasatinib—RIPK2—vagina—ovarian cancer	0.00025	0.00196	CbGeAlD
Dasatinib—LIMK2—testis—ovarian cancer	0.00025	0.00195	CbGeAlD
Dasatinib—YES1—endometrium—ovarian cancer	0.000249	0.00195	CbGeAlD
Dasatinib—MAP4K5—uterus—ovarian cancer	0.000249	0.00195	CbGeAlD
Dasatinib—MAP3K2—bone marrow—ovarian cancer	0.000248	0.00194	CbGeAlD
Dasatinib—MAPK14—female reproductive system—ovarian cancer	0.000247	0.00193	CbGeAlD
Dasatinib—SIK1—female gonad—ovarian cancer	0.000246	0.00192	CbGeAlD
Dasatinib—FGR—female reproductive system—ovarian cancer	0.000246	0.00192	CbGeAlD
Dasatinib—MAP2K5—uterine cervix—ovarian cancer	0.000244	0.00191	CbGeAlD
Dasatinib—EPHA4—female gonad—ovarian cancer	0.000243	0.0019	CbGeAlD
Dasatinib—STK35—testis—ovarian cancer	0.000242	0.00189	CbGeAlD
Dasatinib—ABL1—myometrium—ovarian cancer	0.000242	0.00189	CbGeAlD
Dasatinib—EPHA4—vagina—ovarian cancer	0.000242	0.00189	CbGeAlD
Dasatinib—ERBB3—female gonad—ovarian cancer	0.000241	0.00188	CbGeAlD
Dasatinib—CSK—testis—ovarian cancer	0.000241	0.00188	CbGeAlD
Dasatinib—MAP3K2—female gonad—ovarian cancer	0.000239	0.00187	CbGeAlD
Dasatinib—CSF1R—uterine cervix—ovarian cancer	0.000238	0.00186	CbGeAlD
Dasatinib—EPHA3—lymph node—ovarian cancer	0.000238	0.00186	CbGeAlD
Dasatinib—HCK—testis—ovarian cancer	0.000238	0.00186	CbGeAlD
Dasatinib—ABL2—testis—ovarian cancer	0.000236	0.00184	CbGeAlD
Dasatinib—EPHB4—female reproductive system—ovarian cancer	0.000234	0.00183	CbGeAlD
Dasatinib—MAPK14—bone marrow—ovarian cancer	0.000233	0.00182	CbGeAlD
Dasatinib—ABL1—embryo—ovarian cancer	0.000233	0.00182	CbGeAlD
Dasatinib—MAP2K5—decidua—ovarian cancer	0.000233	0.00182	CbGeAlD
Dasatinib—JAK2—female reproductive system—ovarian cancer	0.000232	0.00181	CbGeAlD
Dasatinib—FGR—bone marrow—ovarian cancer	0.000232	0.00181	CbGeAlD
Dasatinib—LCK—bone marrow—ovarian cancer	0.000232	0.00181	CbGeAlD
Dasatinib—SIK3—lymph node—ovarian cancer	0.000232	0.00181	CbGeAlD
Dasatinib—YES1—gonad—ovarian cancer	0.000231	0.00181	CbGeAlD
Dasatinib—YES1—uterus—ovarian cancer	0.00023	0.0018	CbGeAlD
Dasatinib—EPHA2—female reproductive system—ovarian cancer	0.000229	0.00179	CbGeAlD
Dasatinib—FYN—female reproductive system—ovarian cancer	0.000229	0.00179	CbGeAlD
Dasatinib—PDGFRA—gonad—ovarian cancer	0.000227	0.00177	CbGeAlD
Dasatinib—CSF1R—decidua—ovarian cancer	0.000227	0.00177	CbGeAlD
Dasatinib—PDGFRA—uterus—ovarian cancer	0.000226	0.00176	CbGeAlD
Dasatinib—MAPK14—female gonad—ovarian cancer	0.000224	0.00175	CbGeAlD
Dasatinib—MAP4K5—female reproductive system—ovarian cancer	0.000224	0.00175	CbGeAlD
Dasatinib—MAP3K3—female reproductive system—ovarian cancer	0.000224	0.00175	CbGeAlD
Dasatinib—FGR—female gonad—ovarian cancer	0.000224	0.00175	CbGeAlD
Dasatinib—LCK—female gonad—ovarian cancer	0.000224	0.00175	CbGeAlD
Dasatinib—RIPK2—testis—ovarian cancer	0.000223	0.00175	CbGeAlD
Dasatinib—MAPK14—vagina—ovarian cancer	0.000223	0.00174	CbGeAlD
Dasatinib—SRC—gonad—ovarian cancer	0.000223	0.00174	CbGeAlD
Dasatinib—FGR—vagina—ovarian cancer	0.000222	0.00174	CbGeAlD
Dasatinib—LCK—vagina—ovarian cancer	0.000222	0.00174	CbGeAlD
Dasatinib—MAP2K5—endometrium—ovarian cancer	0.000221	0.00173	CbGeAlD
Dasatinib—EPHB4—bone marrow—ovarian cancer	0.000221	0.00172	CbGeAlD
Dasatinib—JAK2—bone marrow—ovarian cancer	0.000219	0.00171	CbGeAlD
Dasatinib—KIT—epithelium—ovarian cancer	0.000218	0.0017	CbGeAlD
Dasatinib—SIK1—testis—ovarian cancer	0.000218	0.0017	CbGeAlD
Dasatinib—KIT—uterine cervix—ovarian cancer	0.000216	0.00169	CbGeAlD
Dasatinib—FYN—bone marrow—ovarian cancer	0.000216	0.00169	CbGeAlD
Dasatinib—EPHA4—testis—ovarian cancer	0.000216	0.00169	CbGeAlD
Dasatinib—CSF1R—endometrium—ovarian cancer	0.000215	0.00168	CbGeAlD
Dasatinib—ZAK—lymph node—ovarian cancer	0.000215	0.00168	CbGeAlD
Dasatinib—FMO3—vagina—ovarian cancer	0.000215	0.00168	CbGeAlD
Dasatinib—ERBB3—testis—ovarian cancer	0.000214	0.00167	CbGeAlD
Dasatinib—PDGFRB—epithelium—ovarian cancer	0.000213	0.00167	CbGeAlD
Dasatinib—EPHB4—female gonad—ovarian cancer	0.000213	0.00166	CbGeAlD
Dasatinib—MAP3K2—testis—ovarian cancer	0.000212	0.00165	CbGeAlD
Dasatinib—EPHB4—vagina—ovarian cancer	0.000211	0.00165	CbGeAlD
Dasatinib—PDGFRB—uterine cervix—ovarian cancer	0.000211	0.00165	CbGeAlD
Dasatinib—JAK2—female gonad—ovarian cancer	0.000211	0.00165	CbGeAlD
Dasatinib—MAP4K5—bone marrow—ovarian cancer	0.000211	0.00165	CbGeAlD
Dasatinib—MAP3K3—bone marrow—ovarian cancer	0.000211	0.00165	CbGeAlD
Dasatinib—JAK2—vagina—ovarian cancer	0.00021	0.00164	CbGeAlD
Dasatinib—EPHA2—female gonad—ovarian cancer	0.000209	0.00163	CbGeAlD
Dasatinib—FYN—female gonad—ovarian cancer	0.000208	0.00163	CbGeAlD
Dasatinib—EPHA2—vagina—ovarian cancer	0.000207	0.00162	CbGeAlD
Dasatinib—FYN—vagina—ovarian cancer	0.000207	0.00162	CbGeAlD
Dasatinib—YES1—female reproductive system—ovarian cancer	0.000207	0.00161	CbGeAlD
Dasatinib—BMPR1B—lymph node—ovarian cancer	0.000206	0.00161	CbGeAlD
Dasatinib—KIT—decidua—ovarian cancer	0.000206	0.00161	CbGeAlD
Dasatinib—BTK—lymph node—ovarian cancer	0.000205	0.00161	CbGeAlD
Dasatinib—MAP4K5—female gonad—ovarian cancer	0.000204	0.00159	CbGeAlD
Dasatinib—MAP3K3—female gonad—ovarian cancer	0.000204	0.00159	CbGeAlD
Dasatinib—PDGFRA—female reproductive system—ovarian cancer	0.000203	0.00158	CbGeAlD
Dasatinib—TNK2—lymph node—ovarian cancer	0.000202	0.00158	CbGeAlD
Dasatinib—MAP4K5—vagina—ovarian cancer	0.000202	0.00158	CbGeAlD
Dasatinib—MAP3K3—vagina—ovarian cancer	0.000202	0.00158	CbGeAlD
Dasatinib—PDGFRB—decidua—ovarian cancer	0.000201	0.00157	CbGeAlD
Dasatinib—CSF1R—gonad—ovarian cancer	0.0002	0.00156	CbGeAlD
Dasatinib—MAPK14—testis—ovarian cancer	0.000199	0.00156	CbGeAlD
Dasatinib—SRC—female reproductive system—ovarian cancer	0.000199	0.00155	CbGeAlD
Dasatinib—CSF1R—uterus—ovarian cancer	0.000199	0.00155	CbGeAlD
Dasatinib—LCK—testis—ovarian cancer	0.000198	0.00155	CbGeAlD
Dasatinib—FGR—testis—ovarian cancer	0.000198	0.00155	CbGeAlD
Dasatinib—KIT—endometrium—ovarian cancer	0.000196	0.00153	CbGeAlD
Dasatinib—YES1—bone marrow—ovarian cancer	0.000195	0.00152	CbGeAlD
Dasatinib—EPHB6—female gonad—ovarian cancer	0.000195	0.00152	CbGeAlD
Dasatinib—EPHB6—vagina—ovarian cancer	0.000193	0.00151	CbGeAlD
Dasatinib—FMO3—testis—ovarian cancer	0.000191	0.0015	CbGeAlD
Dasatinib—PDGFRB—endometrium—ovarian cancer	0.000191	0.00149	CbGeAlD
Dasatinib—TESK1—lymph node—ovarian cancer	0.00019	0.00149	CbGeAlD
Dasatinib—EPHB4—testis—ovarian cancer	0.000189	0.00147	CbGeAlD
Dasatinib—ABL1—uterine cervix—ovarian cancer	0.000188	0.00147	CbGeAlD
Dasatinib—YES1—female gonad—ovarian cancer	0.000188	0.00147	CbGeAlD
Dasatinib—JAK2—testis—ovarian cancer	0.000187	0.00146	CbGeAlD
Dasatinib—STK36—lymph node—ovarian cancer	0.000187	0.00146	CbGeAlD
Dasatinib—EPHB3—lymph node—ovarian cancer	0.000187	0.00146	CbGeAlD
Dasatinib—YES1—vagina—ovarian cancer	0.000187	0.00146	CbGeAlD
Dasatinib—EPHA2—testis—ovarian cancer	0.000185	0.00145	CbGeAlD
Dasatinib—FYN—testis—ovarian cancer	0.000185	0.00144	CbGeAlD
Dasatinib—PDGFRA—female gonad—ovarian cancer	0.000184	0.00144	CbGeAlD
Dasatinib—PDGFRA—vagina—ovarian cancer	0.000183	0.00143	CbGeAlD
Dasatinib—MAP2K5—female reproductive system—ovarian cancer	0.000183	0.00143	CbGeAlD
Dasatinib—KIT—gonad—ovarian cancer	0.000181	0.00142	CbGeAlD
Dasatinib—LIMK2—lymph node—ovarian cancer	0.000181	0.00142	CbGeAlD
Dasatinib—SRC—female gonad—ovarian cancer	0.000181	0.00141	CbGeAlD
Dasatinib—MAP4K5—testis—ovarian cancer	0.000181	0.00141	CbGeAlD
Dasatinib—MAP3K3—testis—ovarian cancer	0.000181	0.00141	CbGeAlD
Dasatinib—KIT—uterus—ovarian cancer	0.00018	0.00141	CbGeAlD
Dasatinib—ABL1—decidua—ovarian cancer	0.000179	0.0014	CbGeAlD
Dasatinib—CSF1R—female reproductive system—ovarian cancer	0.000178	0.00139	CbGeAlD
Dasatinib—PDGFRB—gonad—ovarian cancer	0.000177	0.00138	CbGeAlD
Dasatinib—PDGFRB—uterus—ovarian cancer	0.000176	0.00138	CbGeAlD
Dasatinib—STK35—lymph node—ovarian cancer	0.000176	0.00137	CbGeAlD
Dasatinib—CSK—lymph node—ovarian cancer	0.000174	0.00136	CbGeAlD
Dasatinib—EPHB6—testis—ovarian cancer	0.000173	0.00135	CbGeAlD
Dasatinib—HCK—lymph node—ovarian cancer	0.000172	0.00135	CbGeAlD
Dasatinib—ABL2—lymph node—ovarian cancer	0.000171	0.00134	CbGeAlD
Dasatinib—ABL1—endometrium—ovarian cancer	0.00017	0.00133	CbGeAlD
Dasatinib—CSK—Doxorubicin—Epirubicin—ovarian cancer	0.000169	0.0475	CbGdCrCtD
Dasatinib—CSK—Daunorubicin—Epirubicin—ovarian cancer	0.000169	0.0475	CbGdCrCtD
Dasatinib—CSF1R—bone marrow—ovarian cancer	0.000169	0.00132	CbGeAlD
Dasatinib—YES1—testis—ovarian cancer	0.000167	0.0013	CbGeAlD
Dasatinib—MAP2K5—female gonad—ovarian cancer	0.000166	0.0013	CbGeAlD
Dasatinib—MAP2K5—vagina—ovarian cancer	0.000165	0.00129	CbGeAlD
Dasatinib—PDGFRA—testis—ovarian cancer	0.000164	0.00128	CbGeAlD
Dasatinib—CSF1R—female gonad—ovarian cancer	0.000162	0.00127	CbGeAlD
Dasatinib—KIT—female reproductive system—ovarian cancer	0.000162	0.00127	CbGeAlD
Dasatinib—RIPK2—lymph node—ovarian cancer	0.000162	0.00126	CbGeAlD
Dasatinib—CSF1R—vagina—ovarian cancer	0.000161	0.00126	CbGeAlD
Dasatinib—SRC—testis—ovarian cancer	0.00016	0.00125	CbGeAlD
Dasatinib—PDGFRB—female reproductive system—ovarian cancer	0.000158	0.00124	CbGeAlD
Dasatinib—SIK1—lymph node—ovarian cancer	0.000158	0.00124	CbGeAlD
Dasatinib—ABL1—gonad—ovarian cancer	0.000158	0.00123	CbGeAlD
Dasatinib—ABL1—uterus—ovarian cancer	0.000157	0.00123	CbGeAlD
Dasatinib—EPHA4—lymph node—ovarian cancer	0.000156	0.00122	CbGeAlD
Dasatinib—CSK—Daunorubicin—Doxorubicin—ovarian cancer	0.000156	0.044	CbGdCrCtD
Dasatinib—CSK—Epirubicin—Doxorubicin—ovarian cancer	0.000156	0.044	CbGdCrCtD
Dasatinib—ERBB3—lymph node—ovarian cancer	0.000155	0.00121	CbGeAlD
Dasatinib—MAP3K2—lymph node—ovarian cancer	0.000153	0.0012	CbGeAlD
Dasatinib—KIT—bone marrow—ovarian cancer	0.000153	0.0012	CbGeAlD
Dasatinib—ABCG2—myometrium—ovarian cancer	0.000153	0.00119	CbGeAlD
Dasatinib—CYP1B1—decidua—ovarian cancer	0.000152	0.00119	CbGeAlD
Dasatinib—PDGFRB—bone marrow—ovarian cancer	0.000149	0.00117	CbGeAlD
Dasatinib—MAP2K5—testis—ovarian cancer	0.000148	0.00115	CbGeAlD
Dasatinib—KIT—female gonad—ovarian cancer	0.000147	0.00115	CbGeAlD
Dasatinib—KIT—vagina—ovarian cancer	0.000147	0.00115	CbGeAlD
Dasatinib—MAPK14—lymph node—ovarian cancer	0.000144	0.00113	CbGeAlD
Dasatinib—CSF1R—testis—ovarian cancer	0.000144	0.00113	CbGeAlD
Dasatinib—PDGFRB—female gonad—ovarian cancer	0.000144	0.00113	CbGeAlD
Dasatinib—FGR—lymph node—ovarian cancer	0.000144	0.00112	CbGeAlD
Dasatinib—LCK—lymph node—ovarian cancer	0.000144	0.00112	CbGeAlD
Dasatinib—PDGFRB—vagina—ovarian cancer	0.000143	0.00112	CbGeAlD
Dasatinib—ABL1—female reproductive system—ovarian cancer	0.000141	0.0011	CbGeAlD
Dasatinib—FMO3—lymph node—ovarian cancer	0.000139	0.00108	CbGeAlD
Dasatinib—EPHB4—lymph node—ovarian cancer	0.000137	0.00107	CbGeAlD
Dasatinib—JAK2—lymph node—ovarian cancer	0.000136	0.00106	CbGeAlD
Dasatinib—EPHA2—lymph node—ovarian cancer	0.000134	0.00105	CbGeAlD
Dasatinib—FYN—lymph node—ovarian cancer	0.000134	0.00105	CbGeAlD
Dasatinib—CYP1B1—gonad—ovarian cancer	0.000134	0.00105	CbGeAlD
Dasatinib—ABL1—bone marrow—ovarian cancer	0.000133	0.00104	CbGeAlD
Dasatinib—CYP1B1—uterus—ovarian cancer	0.000133	0.00104	CbGeAlD
Dasatinib—MAP3K3—lymph node—ovarian cancer	0.000131	0.00102	CbGeAlD
Dasatinib—MAP4K5—lymph node—ovarian cancer	0.000131	0.00102	CbGeAlD
Dasatinib—KIT—testis—ovarian cancer	0.000131	0.00102	CbGeAlD
Dasatinib—ABL1—female gonad—ovarian cancer	0.000128	0.001	CbGeAlD
Dasatinib—PDGFRB—testis—ovarian cancer	0.000128	0.000998	CbGeAlD
Dasatinib—ABL1—vagina—ovarian cancer	0.000128	0.000997	CbGeAlD
Dasatinib—EPHB6—lymph node—ovarian cancer	0.000125	0.000978	CbGeAlD
Dasatinib—YES1—lymph node—ovarian cancer	0.000121	0.000945	CbGeAlD
Dasatinib—CYP1B1—female reproductive system—ovarian cancer	0.000119	0.000934	CbGeAlD
Dasatinib—ABCG2—uterine cervix—ovarian cancer	0.000119	0.000928	CbGeAlD
Dasatinib—PDGFRA—lymph node—ovarian cancer	0.000119	0.000927	CbGeAlD
Dasatinib—ABL1—Daunorubicin—Epirubicin—ovarian cancer	0.000118	0.0332	CbGdCrCtD
Dasatinib—ABL1—Doxorubicin—Epirubicin—ovarian cancer	0.000118	0.0332	CbGdCrCtD
Dasatinib—ABL1—Idarubicin—Epirubicin—ovarian cancer	0.000118	0.0332	CbGdCrCtD
Dasatinib—SRC—lymph node—ovarian cancer	0.000116	0.000909	CbGeAlD
Dasatinib—ABL1—testis—ovarian cancer	0.000114	0.00089	CbGeAlD
Dasatinib—CYP1A1—epithelium—ovarian cancer	0.000114	0.000888	CbGeAlD
Dasatinib—ABCG2—decidua—ovarian cancer	0.000113	0.000884	CbGeAlD
Dasatinib—CYP1A1—uterine cervix—ovarian cancer	0.000113	0.000881	CbGeAlD
Dasatinib—CYP3A5—uterine cervix—ovarian cancer	0.00011	0.000861	CbGeAlD
Dasatinib—ABL1—Idarubicin—Doxorubicin—ovarian cancer	0.000109	0.0307	CbGdCrCtD
Dasatinib—ABL1—Epirubicin—Doxorubicin—ovarian cancer	0.000109	0.0307	CbGdCrCtD
Dasatinib—ABL1—Daunorubicin—Doxorubicin—ovarian cancer	0.000109	0.0307	CbGdCrCtD
Dasatinib—CYP1B1—female gonad—ovarian cancer	0.000109	0.00085	CbGeAlD
Dasatinib—ABCG2—endometrium—ovarian cancer	0.000107	0.000839	CbGeAlD
Dasatinib—MAP2K5—lymph node—ovarian cancer	0.000107	0.000836	CbGeAlD
Dasatinib—CSF1R—lymph node—ovarian cancer	0.000104	0.000816	CbGeAlD
Dasatinib—ABCG2—uterus—ovarian cancer	9.9e-05	0.000773	CbGeAlD
Dasatinib—CYP1B1—testis—ovarian cancer	9.64e-05	0.000753	CbGeAlD
Dasatinib—KIT—lymph node—ovarian cancer	9.48e-05	0.000741	CbGeAlD
Dasatinib—CYP1A1—uterus—ovarian cancer	9.4e-05	0.000734	CbGeAlD
Dasatinib—PDGFRB—lymph node—ovarian cancer	9.26e-05	0.000724	CbGeAlD
Dasatinib—CYP1A1—female reproductive system—ovarian cancer	8.45e-05	0.00066	CbGeAlD
Dasatinib—ABCG2—bone marrow—ovarian cancer	8.4e-05	0.000656	CbGeAlD
Dasatinib—ABL1—lymph node—ovarian cancer	8.25e-05	0.000645	CbGeAlD
Dasatinib—ABCG2—female gonad—ovarian cancer	8.1e-05	0.000633	CbGeAlD
Dasatinib—ABCG2—vagina—ovarian cancer	8.05e-05	0.000629	CbGeAlD
Dasatinib—CYP1A1—female gonad—ovarian cancer	7.69e-05	0.000601	CbGeAlD
Dasatinib—CYP1A1—vagina—ovarian cancer	7.64e-05	0.000597	CbGeAlD
Dasatinib—ABCB1—myometrium—ovarian cancer	7.52e-05	0.000588	CbGeAlD
Dasatinib—CYP3A5—female gonad—ovarian cancer	7.51e-05	0.000587	CbGeAlD
Dasatinib—CYP3A5—vagina—ovarian cancer	7.47e-05	0.000584	CbGeAlD
Dasatinib—ABCB1—embryo—ovarian cancer	7.24e-05	0.000566	CbGeAlD
Dasatinib—ABCG2—testis—ovarian cancer	7.18e-05	0.000561	CbGeAlD
Dasatinib—CYP1B1—lymph node—ovarian cancer	6.99e-05	0.000546	CbGeAlD
Dasatinib—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	6.49e-05	0.000422	CcSEcCtD
Dasatinib—Weight decreased—Epirubicin—ovarian cancer	6.48e-05	0.000422	CcSEcCtD
Dasatinib—Cough—Docetaxel—ovarian cancer	6.46e-05	0.00042	CcSEcCtD
Dasatinib—Angina pectoris—Doxorubicin—ovarian cancer	6.46e-05	0.00042	CcSEcCtD
Dasatinib—Insomnia—Paclitaxel—ovarian cancer	6.44e-05	0.000419	CcSEcCtD
Dasatinib—Pneumonia—Epirubicin—ovarian cancer	6.42e-05	0.000418	CcSEcCtD
Dasatinib—Convulsion—Docetaxel—ovarian cancer	6.41e-05	0.000417	CcSEcCtD
Dasatinib—Hypertension—Docetaxel—ovarian cancer	6.39e-05	0.000416	CcSEcCtD
Dasatinib—Infestation—Epirubicin—ovarian cancer	6.39e-05	0.000415	CcSEcCtD
Dasatinib—Infestation NOS—Epirubicin—ovarian cancer	6.39e-05	0.000415	CcSEcCtD
Dasatinib—Dyspnoea—Paclitaxel—ovarian cancer	6.35e-05	0.000413	CcSEcCtD
Dasatinib—Somnolence—Paclitaxel—ovarian cancer	6.33e-05	0.000412	CcSEcCtD
Dasatinib—Arthralgia—Docetaxel—ovarian cancer	6.3e-05	0.00041	CcSEcCtD
Dasatinib—Myalgia—Docetaxel—ovarian cancer	6.3e-05	0.00041	CcSEcCtD
Dasatinib—Chest pain—Docetaxel—ovarian cancer	6.3e-05	0.00041	CcSEcCtD
Dasatinib—Pancytopenia—Doxorubicin—ovarian cancer	6.29e-05	0.000409	CcSEcCtD
Dasatinib—Nausea—Vinorelbine—ovarian cancer	6.29e-05	0.000409	CcSEcCtD
Dasatinib—Renal failure—Epirubicin—ovarian cancer	6.28e-05	0.000408	CcSEcCtD
Dasatinib—Dyspepsia—Paclitaxel—ovarian cancer	6.27e-05	0.000408	CcSEcCtD
Dasatinib—Neuropathy peripheral—Epirubicin—ovarian cancer	6.26e-05	0.000407	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	6.26e-05	0.000407	CcSEcCtD
Dasatinib—Stomatitis—Epirubicin—ovarian cancer	6.23e-05	0.000405	CcSEcCtD
Dasatinib—Conjunctivitis—Epirubicin—ovarian cancer	6.21e-05	0.000404	CcSEcCtD
Dasatinib—CYP3A4—female reproductive system—ovarian cancer	6.2e-05	0.000484	CbGeAlD
Dasatinib—Neutropenia—Doxorubicin—ovarian cancer	6.2e-05	0.000403	CcSEcCtD
Dasatinib—Decreased appetite—Paclitaxel—ovarian cancer	6.19e-05	0.000403	CcSEcCtD
Dasatinib—Upper respiratory tract infection—Doxorubicin—ovarian cancer	6.16e-05	0.000401	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Paclitaxel—ovarian cancer	6.15e-05	0.0004	CcSEcCtD
Dasatinib—Fatigue—Paclitaxel—ovarian cancer	6.14e-05	0.0004	CcSEcCtD
Dasatinib—Pollakiuria—Doxorubicin—ovarian cancer	6.12e-05	0.000398	CcSEcCtD
Dasatinib—Pain—Paclitaxel—ovarian cancer	6.09e-05	0.000396	CcSEcCtD
Dasatinib—Constipation—Paclitaxel—ovarian cancer	6.09e-05	0.000396	CcSEcCtD
Dasatinib—Haematuria—Epirubicin—ovarian cancer	6.09e-05	0.000396	CcSEcCtD
Dasatinib—Confusional state—Docetaxel—ovarian cancer	6.09e-05	0.000396	CcSEcCtD
Dasatinib—Photosensitivity reaction—Doxorubicin—ovarian cancer	6.05e-05	0.000394	CcSEcCtD
Dasatinib—Hepatobiliary disease—Epirubicin—ovarian cancer	6.04e-05	0.000393	CcSEcCtD
Dasatinib—Oedema—Docetaxel—ovarian cancer	6.04e-05	0.000393	CcSEcCtD
Dasatinib—Weight increased—Doxorubicin—ovarian cancer	6.03e-05	0.000392	CcSEcCtD
Dasatinib—Epistaxis—Epirubicin—ovarian cancer	6.02e-05	0.000392	CcSEcCtD
Dasatinib—Infection—Docetaxel—ovarian cancer	6e-05	0.00039	CcSEcCtD
Dasatinib—Weight decreased—Doxorubicin—ovarian cancer	6e-05	0.00039	CcSEcCtD
Dasatinib—Pneumonia—Doxorubicin—ovarian cancer	5.94e-05	0.000387	CcSEcCtD
Dasatinib—Shock—Docetaxel—ovarian cancer	5.94e-05	0.000387	CcSEcCtD
Dasatinib—Nervous system disorder—Docetaxel—ovarian cancer	5.92e-05	0.000385	CcSEcCtD
Dasatinib—Thrombocytopenia—Docetaxel—ovarian cancer	5.91e-05	0.000385	CcSEcCtD
Dasatinib—Infestation NOS—Doxorubicin—ovarian cancer	5.91e-05	0.000384	CcSEcCtD
Dasatinib—Infestation—Doxorubicin—ovarian cancer	5.91e-05	0.000384	CcSEcCtD
Dasatinib—ABCB1—epithelium—ovarian cancer	5.91e-05	0.000461	CbGeAlD
Dasatinib—Tachycardia—Docetaxel—ovarian cancer	5.89e-05	0.000383	CcSEcCtD
Dasatinib—Feeling abnormal—Paclitaxel—ovarian cancer	5.87e-05	0.000382	CcSEcCtD
Dasatinib—Skin disorder—Docetaxel—ovarian cancer	5.87e-05	0.000382	CcSEcCtD
Dasatinib—ABCB1—uterine cervix—ovarian cancer	5.86e-05	0.000458	CbGeAlD
Dasatinib—Gastrointestinal pain—Paclitaxel—ovarian cancer	5.83e-05	0.000379	CcSEcCtD
Dasatinib—Renal failure—Doxorubicin—ovarian cancer	5.81e-05	0.000378	CcSEcCtD
Dasatinib—Neuropathy peripheral—Doxorubicin—ovarian cancer	5.79e-05	0.000377	CcSEcCtD
Dasatinib—Haemoglobin—Epirubicin—ovarian cancer	5.76e-05	0.000375	CcSEcCtD
Dasatinib—Stomatitis—Doxorubicin—ovarian cancer	5.76e-05	0.000375	CcSEcCtD
Dasatinib—Anorexia—Docetaxel—ovarian cancer	5.76e-05	0.000374	CcSEcCtD
Dasatinib—Conjunctivitis—Doxorubicin—ovarian cancer	5.74e-05	0.000374	CcSEcCtD
Dasatinib—Haemorrhage—Epirubicin—ovarian cancer	5.73e-05	0.000373	CcSEcCtD
Dasatinib—Hepatitis—Epirubicin—ovarian cancer	5.73e-05	0.000373	CcSEcCtD
Dasatinib—Urinary tract disorder—Epirubicin—ovarian cancer	5.66e-05	0.000368	CcSEcCtD
Dasatinib—Urticaria—Paclitaxel—ovarian cancer	5.66e-05	0.000368	CcSEcCtD
Dasatinib—Oedema peripheral—Epirubicin—ovarian cancer	5.65e-05	0.000367	CcSEcCtD
Dasatinib—Hypotension—Docetaxel—ovarian cancer	5.64e-05	0.000367	CcSEcCtD
Dasatinib—Haematuria—Doxorubicin—ovarian cancer	5.63e-05	0.000367	CcSEcCtD
Dasatinib—Connective tissue disorder—Epirubicin—ovarian cancer	5.63e-05	0.000367	CcSEcCtD
Dasatinib—Abdominal pain—Paclitaxel—ovarian cancer	5.63e-05	0.000366	CcSEcCtD
Dasatinib—Body temperature increased—Paclitaxel—ovarian cancer	5.63e-05	0.000366	CcSEcCtD
Dasatinib—Urethral disorder—Epirubicin—ovarian cancer	5.62e-05	0.000366	CcSEcCtD
Dasatinib—Hepatobiliary disease—Doxorubicin—ovarian cancer	5.59e-05	0.000364	CcSEcCtD
Dasatinib—ABCB1—decidua—ovarian cancer	5.58e-05	0.000436	CbGeAlD
Dasatinib—Epistaxis—Doxorubicin—ovarian cancer	5.57e-05	0.000363	CcSEcCtD
Dasatinib—Visual impairment—Epirubicin—ovarian cancer	5.53e-05	0.000359	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Docetaxel—ovarian cancer	5.5e-05	0.000358	CcSEcCtD
Dasatinib—Insomnia—Docetaxel—ovarian cancer	5.46e-05	0.000355	CcSEcCtD
Dasatinib—Erythema multiforme—Epirubicin—ovarian cancer	5.42e-05	0.000353	CcSEcCtD
Dasatinib—Dyspnoea—Docetaxel—ovarian cancer	5.38e-05	0.00035	CcSEcCtD
Dasatinib—Somnolence—Docetaxel—ovarian cancer	5.37e-05	0.000349	CcSEcCtD
Dasatinib—Eye disorder—Epirubicin—ovarian cancer	5.36e-05	0.000349	CcSEcCtD
Dasatinib—Tinnitus—Epirubicin—ovarian cancer	5.35e-05	0.000348	CcSEcCtD
Dasatinib—Haemoglobin—Doxorubicin—ovarian cancer	5.33e-05	0.000347	CcSEcCtD
Dasatinib—Cardiac disorder—Epirubicin—ovarian cancer	5.32e-05	0.000346	CcSEcCtD
Dasatinib—Flushing—Epirubicin—ovarian cancer	5.32e-05	0.000346	CcSEcCtD
Dasatinib—Dyspepsia—Docetaxel—ovarian cancer	5.32e-05	0.000346	CcSEcCtD
Dasatinib—Hepatitis—Doxorubicin—ovarian cancer	5.3e-05	0.000345	CcSEcCtD
Dasatinib—Haemorrhage—Doxorubicin—ovarian cancer	5.3e-05	0.000345	CcSEcCtD
Dasatinib—ABCB1—endometrium—ovarian cancer	5.3e-05	0.000414	CbGeAlD
Dasatinib—Decreased appetite—Docetaxel—ovarian cancer	5.25e-05	0.000342	CcSEcCtD
Dasatinib—Hypersensitivity—Paclitaxel—ovarian cancer	5.25e-05	0.000341	CcSEcCtD
Dasatinib—Urinary tract disorder—Doxorubicin—ovarian cancer	5.24e-05	0.000341	CcSEcCtD
Dasatinib—Oedema peripheral—Doxorubicin—ovarian cancer	5.23e-05	0.00034	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Docetaxel—ovarian cancer	5.21e-05	0.000339	CcSEcCtD
Dasatinib—Connective tissue disorder—Doxorubicin—ovarian cancer	5.21e-05	0.000339	CcSEcCtD
Dasatinib—Fatigue—Docetaxel—ovarian cancer	5.21e-05	0.000339	CcSEcCtD
Dasatinib—ABCG2—lymph node—ovarian cancer	5.2e-05	0.000407	CbGeAlD
Dasatinib—Angiopathy—Epirubicin—ovarian cancer	5.2e-05	0.000338	CcSEcCtD
Dasatinib—Urethral disorder—Doxorubicin—ovarian cancer	5.2e-05	0.000338	CcSEcCtD
Dasatinib—Immune system disorder—Epirubicin—ovarian cancer	5.18e-05	0.000337	CcSEcCtD
Dasatinib—Mediastinal disorder—Epirubicin—ovarian cancer	5.17e-05	0.000336	CcSEcCtD
Dasatinib—Constipation—Docetaxel—ovarian cancer	5.16e-05	0.000336	CcSEcCtD
Dasatinib—Pain—Docetaxel—ovarian cancer	5.16e-05	0.000336	CcSEcCtD
Dasatinib—Chills—Epirubicin—ovarian cancer	5.14e-05	0.000335	CcSEcCtD
Dasatinib—Arrhythmia—Epirubicin—ovarian cancer	5.12e-05	0.000333	CcSEcCtD
Dasatinib—Visual impairment—Doxorubicin—ovarian cancer	5.11e-05	0.000333	CcSEcCtD
Dasatinib—Asthenia—Paclitaxel—ovarian cancer	5.11e-05	0.000333	CcSEcCtD
Dasatinib—Alopecia—Epirubicin—ovarian cancer	5.07e-05	0.00033	CcSEcCtD
Dasatinib—Pruritus—Paclitaxel—ovarian cancer	5.04e-05	0.000328	CcSEcCtD
Dasatinib—Mental disorder—Epirubicin—ovarian cancer	5.02e-05	0.000327	CcSEcCtD
Dasatinib—Erythema multiforme—Doxorubicin—ovarian cancer	5.02e-05	0.000326	CcSEcCtD
Dasatinib—Malnutrition—Epirubicin—ovarian cancer	4.99e-05	0.000325	CcSEcCtD
Dasatinib—Erythema—Epirubicin—ovarian cancer	4.99e-05	0.000325	CcSEcCtD
Dasatinib—Feeling abnormal—Docetaxel—ovarian cancer	4.98e-05	0.000324	CcSEcCtD
Dasatinib—Eye disorder—Doxorubicin—ovarian cancer	4.96e-05	0.000323	CcSEcCtD
Dasatinib—Tinnitus—Doxorubicin—ovarian cancer	4.95e-05	0.000322	CcSEcCtD
Dasatinib—CYP1A1—lymph node—ovarian cancer	4.94e-05	0.000386	CbGeAlD
Dasatinib—Gastrointestinal pain—Docetaxel—ovarian cancer	4.94e-05	0.000321	CcSEcCtD
Dasatinib—Flushing—Doxorubicin—ovarian cancer	4.92e-05	0.00032	CcSEcCtD
Dasatinib—Cardiac disorder—Doxorubicin—ovarian cancer	4.92e-05	0.00032	CcSEcCtD
Dasatinib—ABCB1—gonad—ovarian cancer	4.91e-05	0.000384	CbGeAlD
Dasatinib—Dysgeusia—Epirubicin—ovarian cancer	4.89e-05	0.000318	CcSEcCtD
Dasatinib—ABCB1—uterus—ovarian cancer	4.88e-05	0.000381	CbGeAlD
Dasatinib—Diarrhoea—Paclitaxel—ovarian cancer	4.87e-05	0.000317	CcSEcCtD
Dasatinib—Angiopathy—Doxorubicin—ovarian cancer	4.81e-05	0.000313	CcSEcCtD
Dasatinib—Muscle spasms—Epirubicin—ovarian cancer	4.8e-05	0.000312	CcSEcCtD
Dasatinib—Immune system disorder—Doxorubicin—ovarian cancer	4.79e-05	0.000312	CcSEcCtD
Dasatinib—Mediastinal disorder—Doxorubicin—ovarian cancer	4.78e-05	0.000311	CcSEcCtD
Dasatinib—Body temperature increased—Docetaxel—ovarian cancer	4.77e-05	0.000311	CcSEcCtD
Dasatinib—Abdominal pain—Docetaxel—ovarian cancer	4.77e-05	0.000311	CcSEcCtD
Dasatinib—Chills—Doxorubicin—ovarian cancer	4.76e-05	0.00031	CcSEcCtD
Dasatinib—Arrhythmia—Doxorubicin—ovarian cancer	4.74e-05	0.000308	CcSEcCtD
Dasatinib—Dizziness—Paclitaxel—ovarian cancer	4.71e-05	0.000307	CcSEcCtD
Dasatinib—Vision blurred—Epirubicin—ovarian cancer	4.7e-05	0.000306	CcSEcCtD
Dasatinib—Alopecia—Doxorubicin—ovarian cancer	4.69e-05	0.000305	CcSEcCtD
Dasatinib—Mental disorder—Doxorubicin—ovarian cancer	4.65e-05	0.000302	CcSEcCtD
Dasatinib—Ill-defined disorder—Epirubicin—ovarian cancer	4.63e-05	0.000301	CcSEcCtD
Dasatinib—Malnutrition—Doxorubicin—ovarian cancer	4.62e-05	0.0003	CcSEcCtD
Dasatinib—Erythema—Doxorubicin—ovarian cancer	4.62e-05	0.0003	CcSEcCtD
Dasatinib—Anaemia—Epirubicin—ovarian cancer	4.61e-05	0.0003	CcSEcCtD
Dasatinib—Vomiting—Paclitaxel—ovarian cancer	4.53e-05	0.000295	CcSEcCtD
Dasatinib—Dysgeusia—Doxorubicin—ovarian cancer	4.52e-05	0.000294	CcSEcCtD
Dasatinib—Malaise—Epirubicin—ovarian cancer	4.5e-05	0.000293	CcSEcCtD
Dasatinib—Rash—Paclitaxel—ovarian cancer	4.49e-05	0.000292	CcSEcCtD
Dasatinib—Dermatitis—Paclitaxel—ovarian cancer	4.49e-05	0.000292	CcSEcCtD
Dasatinib—Vertigo—Epirubicin—ovarian cancer	4.48e-05	0.000292	CcSEcCtD
Dasatinib—Syncope—Epirubicin—ovarian cancer	4.48e-05	0.000291	CcSEcCtD
Dasatinib—Headache—Paclitaxel—ovarian cancer	4.46e-05	0.00029	CcSEcCtD
Dasatinib—Hypersensitivity—Docetaxel—ovarian cancer	4.45e-05	0.000289	CcSEcCtD
Dasatinib—Muscle spasms—Doxorubicin—ovarian cancer	4.44e-05	0.000289	CcSEcCtD
Dasatinib—Palpitations—Epirubicin—ovarian cancer	4.41e-05	0.000287	CcSEcCtD
Dasatinib—ABCB1—female reproductive system—ovarian cancer	4.39e-05	0.000343	CbGeAlD
Dasatinib—Loss of consciousness—Epirubicin—ovarian cancer	4.39e-05	0.000285	CcSEcCtD
Dasatinib—Cough—Epirubicin—ovarian cancer	4.36e-05	0.000283	CcSEcCtD
Dasatinib—Vision blurred—Doxorubicin—ovarian cancer	4.35e-05	0.000283	CcSEcCtD
Dasatinib—Asthenia—Docetaxel—ovarian cancer	4.33e-05	0.000282	CcSEcCtD
Dasatinib—Convulsion—Epirubicin—ovarian cancer	4.32e-05	0.000281	CcSEcCtD
Dasatinib—Hypertension—Epirubicin—ovarian cancer	4.31e-05	0.00028	CcSEcCtD
Dasatinib—Ill-defined disorder—Doxorubicin—ovarian cancer	4.28e-05	0.000279	CcSEcCtD
Dasatinib—Pruritus—Docetaxel—ovarian cancer	4.27e-05	0.000278	CcSEcCtD
Dasatinib—Anaemia—Doxorubicin—ovarian cancer	4.27e-05	0.000278	CcSEcCtD
Dasatinib—Arthralgia—Epirubicin—ovarian cancer	4.25e-05	0.000276	CcSEcCtD
Dasatinib—Chest pain—Epirubicin—ovarian cancer	4.25e-05	0.000276	CcSEcCtD
Dasatinib—Myalgia—Epirubicin—ovarian cancer	4.25e-05	0.000276	CcSEcCtD
Dasatinib—Anxiety—Epirubicin—ovarian cancer	4.23e-05	0.000275	CcSEcCtD
Dasatinib—Nausea—Paclitaxel—ovarian cancer	4.23e-05	0.000275	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	4.22e-05	0.000275	CcSEcCtD
Dasatinib—Discomfort—Epirubicin—ovarian cancer	4.2e-05	0.000273	CcSEcCtD
Dasatinib—Malaise—Doxorubicin—ovarian cancer	4.16e-05	0.000271	CcSEcCtD
Dasatinib—Vertigo—Doxorubicin—ovarian cancer	4.15e-05	0.00027	CcSEcCtD
Dasatinib—ABCB1—bone marrow—ovarian cancer	4.14e-05	0.000324	CbGeAlD
Dasatinib—Syncope—Doxorubicin—ovarian cancer	4.14e-05	0.000269	CcSEcCtD
Dasatinib—Diarrhoea—Docetaxel—ovarian cancer	4.13e-05	0.000269	CcSEcCtD
Dasatinib—Confusional state—Epirubicin—ovarian cancer	4.11e-05	0.000267	CcSEcCtD
Dasatinib—Palpitations—Doxorubicin—ovarian cancer	4.08e-05	0.000265	CcSEcCtD
Dasatinib—Oedema—Epirubicin—ovarian cancer	4.07e-05	0.000265	CcSEcCtD
Dasatinib—Loss of consciousness—Doxorubicin—ovarian cancer	4.06e-05	0.000264	CcSEcCtD
Dasatinib—Infection—Epirubicin—ovarian cancer	4.05e-05	0.000263	CcSEcCtD
Dasatinib—Cough—Doxorubicin—ovarian cancer	4.03e-05	0.000262	CcSEcCtD
Dasatinib—Shock—Epirubicin—ovarian cancer	4.01e-05	0.000261	CcSEcCtD
Dasatinib—Convulsion—Doxorubicin—ovarian cancer	4e-05	0.00026	CcSEcCtD
Dasatinib—Nervous system disorder—Epirubicin—ovarian cancer	3.99e-05	0.00026	CcSEcCtD
Dasatinib—Dizziness—Docetaxel—ovarian cancer	3.99e-05	0.00026	CcSEcCtD
Dasatinib—ABCB1—female gonad—ovarian cancer	3.99e-05	0.000312	CbGeAlD
Dasatinib—Thrombocytopenia—Epirubicin—ovarian cancer	3.99e-05	0.000259	CcSEcCtD
Dasatinib—Hypertension—Doxorubicin—ovarian cancer	3.99e-05	0.000259	CcSEcCtD
Dasatinib—Tachycardia—Epirubicin—ovarian cancer	3.98e-05	0.000259	CcSEcCtD
Dasatinib—ABCB1—vagina—ovarian cancer	3.97e-05	0.00031	CbGeAlD
Dasatinib—Skin disorder—Epirubicin—ovarian cancer	3.96e-05	0.000257	CcSEcCtD
Dasatinib—Hyperhidrosis—Epirubicin—ovarian cancer	3.94e-05	0.000256	CcSEcCtD
Dasatinib—Arthralgia—Doxorubicin—ovarian cancer	3.93e-05	0.000256	CcSEcCtD
Dasatinib—Chest pain—Doxorubicin—ovarian cancer	3.93e-05	0.000256	CcSEcCtD
Dasatinib—Myalgia—Doxorubicin—ovarian cancer	3.93e-05	0.000256	CcSEcCtD
Dasatinib—Anxiety—Doxorubicin—ovarian cancer	3.92e-05	0.000255	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	3.9e-05	0.000254	CcSEcCtD
Dasatinib—Discomfort—Doxorubicin—ovarian cancer	3.88e-05	0.000253	CcSEcCtD
Dasatinib—Anorexia—Epirubicin—ovarian cancer	3.88e-05	0.000253	CcSEcCtD
Dasatinib—Vomiting—Docetaxel—ovarian cancer	3.84e-05	0.00025	CcSEcCtD
Dasatinib—Rash—Docetaxel—ovarian cancer	3.81e-05	0.000248	CcSEcCtD
Dasatinib—Hypotension—Epirubicin—ovarian cancer	3.81e-05	0.000248	CcSEcCtD
Dasatinib—Dermatitis—Docetaxel—ovarian cancer	3.8e-05	0.000247	CcSEcCtD
Dasatinib—Confusional state—Doxorubicin—ovarian cancer	3.8e-05	0.000247	CcSEcCtD
Dasatinib—Headache—Docetaxel—ovarian cancer	3.78e-05	0.000246	CcSEcCtD
Dasatinib—Oedema—Doxorubicin—ovarian cancer	3.77e-05	0.000245	CcSEcCtD
Dasatinib—Infection—Doxorubicin—ovarian cancer	3.74e-05	0.000244	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Epirubicin—ovarian cancer	3.71e-05	0.000241	CcSEcCtD
Dasatinib—Shock—Doxorubicin—ovarian cancer	3.71e-05	0.000241	CcSEcCtD
Dasatinib—Nervous system disorder—Doxorubicin—ovarian cancer	3.7e-05	0.00024	CcSEcCtD
Dasatinib—Thrombocytopenia—Doxorubicin—ovarian cancer	3.69e-05	0.00024	CcSEcCtD
Dasatinib—Insomnia—Epirubicin—ovarian cancer	3.68e-05	0.00024	CcSEcCtD
Dasatinib—Tachycardia—Doxorubicin—ovarian cancer	3.68e-05	0.000239	CcSEcCtD
Dasatinib—Skin disorder—Doxorubicin—ovarian cancer	3.66e-05	0.000238	CcSEcCtD
Dasatinib—Hyperhidrosis—Doxorubicin—ovarian cancer	3.64e-05	0.000237	CcSEcCtD
Dasatinib—Dyspnoea—Epirubicin—ovarian cancer	3.63e-05	0.000236	CcSEcCtD
Dasatinib—Somnolence—Epirubicin—ovarian cancer	3.62e-05	0.000236	CcSEcCtD
Dasatinib—Anorexia—Doxorubicin—ovarian cancer	3.59e-05	0.000234	CcSEcCtD
Dasatinib—Nausea—Docetaxel—ovarian cancer	3.59e-05	0.000233	CcSEcCtD
Dasatinib—Dyspepsia—Epirubicin—ovarian cancer	3.59e-05	0.000233	CcSEcCtD
Dasatinib—Decreased appetite—Epirubicin—ovarian cancer	3.54e-05	0.00023	CcSEcCtD
Dasatinib—ABCB1—testis—ovarian cancer	3.54e-05	0.000277	CbGeAlD
Dasatinib—Hypotension—Doxorubicin—ovarian cancer	3.52e-05	0.000229	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Epirubicin—ovarian cancer	3.52e-05	0.000229	CcSEcCtD
Dasatinib—Fatigue—Epirubicin—ovarian cancer	3.51e-05	0.000228	CcSEcCtD
Dasatinib—Constipation—Epirubicin—ovarian cancer	3.48e-05	0.000227	CcSEcCtD
Dasatinib—Pain—Epirubicin—ovarian cancer	3.48e-05	0.000227	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	3.43e-05	0.000223	CcSEcCtD
Dasatinib—Insomnia—Doxorubicin—ovarian cancer	3.41e-05	0.000222	CcSEcCtD
Dasatinib—Dyspnoea—Doxorubicin—ovarian cancer	3.36e-05	0.000219	CcSEcCtD
Dasatinib—Feeling abnormal—Epirubicin—ovarian cancer	3.36e-05	0.000218	CcSEcCtD
Dasatinib—Somnolence—Doxorubicin—ovarian cancer	3.35e-05	0.000218	CcSEcCtD
Dasatinib—Gastrointestinal pain—Epirubicin—ovarian cancer	3.33e-05	0.000217	CcSEcCtD
Dasatinib—Dyspepsia—Doxorubicin—ovarian cancer	3.32e-05	0.000216	CcSEcCtD
Dasatinib—Decreased appetite—Doxorubicin—ovarian cancer	3.28e-05	0.000213	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Doxorubicin—ovarian cancer	3.25e-05	0.000212	CcSEcCtD
Dasatinib—Fatigue—Doxorubicin—ovarian cancer	3.25e-05	0.000211	CcSEcCtD
Dasatinib—Urticaria—Epirubicin—ovarian cancer	3.24e-05	0.000211	CcSEcCtD
Dasatinib—Pain—Doxorubicin—ovarian cancer	3.22e-05	0.00021	CcSEcCtD
Dasatinib—Constipation—Doxorubicin—ovarian cancer	3.22e-05	0.00021	CcSEcCtD
Dasatinib—Abdominal pain—Epirubicin—ovarian cancer	3.22e-05	0.000209	CcSEcCtD
Dasatinib—Body temperature increased—Epirubicin—ovarian cancer	3.22e-05	0.000209	CcSEcCtD
Dasatinib—Feeling abnormal—Doxorubicin—ovarian cancer	3.11e-05	0.000202	CcSEcCtD
Dasatinib—Gastrointestinal pain—Doxorubicin—ovarian cancer	3.08e-05	0.0002	CcSEcCtD
Dasatinib—Hypersensitivity—Epirubicin—ovarian cancer	3e-05	0.000195	CcSEcCtD
Dasatinib—Urticaria—Doxorubicin—ovarian cancer	2.99e-05	0.000195	CcSEcCtD
Dasatinib—Abdominal pain—Doxorubicin—ovarian cancer	2.98e-05	0.000194	CcSEcCtD
Dasatinib—Body temperature increased—Doxorubicin—ovarian cancer	2.98e-05	0.000194	CcSEcCtD
Dasatinib—Asthenia—Epirubicin—ovarian cancer	2.92e-05	0.00019	CcSEcCtD
Dasatinib—Pruritus—Epirubicin—ovarian cancer	2.88e-05	0.000187	CcSEcCtD
Dasatinib—Diarrhoea—Epirubicin—ovarian cancer	2.79e-05	0.000181	CcSEcCtD
Dasatinib—Hypersensitivity—Doxorubicin—ovarian cancer	2.78e-05	0.000181	CcSEcCtD
Dasatinib—Asthenia—Doxorubicin—ovarian cancer	2.7e-05	0.000176	CcSEcCtD
Dasatinib—Dizziness—Epirubicin—ovarian cancer	2.69e-05	0.000175	CcSEcCtD
Dasatinib—Pruritus—Doxorubicin—ovarian cancer	2.67e-05	0.000173	CcSEcCtD
Dasatinib—Vomiting—Epirubicin—ovarian cancer	2.59e-05	0.000168	CcSEcCtD
Dasatinib—Diarrhoea—Doxorubicin—ovarian cancer	2.58e-05	0.000168	CcSEcCtD
Dasatinib—Rash—Epirubicin—ovarian cancer	2.57e-05	0.000167	CcSEcCtD
Dasatinib—ABCB1—lymph node—ovarian cancer	2.57e-05	0.000201	CbGeAlD
Dasatinib—Dermatitis—Epirubicin—ovarian cancer	2.57e-05	0.000167	CcSEcCtD
Dasatinib—Headache—Epirubicin—ovarian cancer	2.55e-05	0.000166	CcSEcCtD
Dasatinib—Dizziness—Doxorubicin—ovarian cancer	2.49e-05	0.000162	CcSEcCtD
Dasatinib—Nausea—Epirubicin—ovarian cancer	2.42e-05	0.000157	CcSEcCtD
Dasatinib—Vomiting—Doxorubicin—ovarian cancer	2.4e-05	0.000156	CcSEcCtD
Dasatinib—Rash—Doxorubicin—ovarian cancer	2.38e-05	0.000155	CcSEcCtD
Dasatinib—Dermatitis—Doxorubicin—ovarian cancer	2.37e-05	0.000154	CcSEcCtD
Dasatinib—Headache—Doxorubicin—ovarian cancer	2.36e-05	0.000154	CcSEcCtD
Dasatinib—Nausea—Doxorubicin—ovarian cancer	2.24e-05	0.000146	CcSEcCtD
Dasatinib—MAPK14—Signaling Pathways—CTNNB1—ovarian cancer	9.36e-07	4.84e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CG—ovarian cancer	9.35e-07	4.83e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CCND1—ovarian cancer	9.33e-07	4.82e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MAPK3—ovarian cancer	9.33e-07	4.82e-06	CbGpPWpGaD
Dasatinib—LYN—Immune System—IL6—ovarian cancer	9.3e-07	4.8e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PIK3CD—ovarian cancer	9.27e-07	4.79e-06	CbGpPWpGaD
Dasatinib—ABL1—Immune System—IL6—ovarian cancer	9.26e-07	4.78e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—ERBB2—ovarian cancer	9.25e-07	4.78e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CTNNB1—ovarian cancer	9.24e-07	4.77e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—MAPK3—ovarian cancer	9.23e-07	4.77e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—HRAS—ovarian cancer	9.21e-07	4.76e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—IL6—ovarian cancer	9.19e-07	4.75e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MMP9—ovarian cancer	9.18e-07	4.74e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—HRAS—ovarian cancer	9.16e-07	4.73e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—MAPK1—ovarian cancer	9.16e-07	4.73e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—EGFR—ovarian cancer	9.16e-07	4.73e-06	CbGpPWpGaD
Dasatinib—FYN—Immune System—IL6—ovarian cancer	9.16e-07	4.73e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PTEN—ovarian cancer	9.14e-07	4.72e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PIK3CB—ovarian cancer	9.13e-07	4.72e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MTOR—ovarian cancer	9.13e-07	4.72e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—PTEN—ovarian cancer	9.13e-07	4.71e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—PIK3CA—ovarian cancer	9.11e-07	4.7e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—HRAS—ovarian cancer	9.09e-07	4.7e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—PIK3CA—ovarian cancer	9.08e-07	4.69e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MYC—ovarian cancer	9.07e-07	4.69e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MMP9—ovarian cancer	9.06e-07	4.68e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—PTEN—ovarian cancer	9.01e-07	4.65e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—AKT1—ovarian cancer	8.98e-07	4.64e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—STAT3—ovarian cancer	8.92e-07	4.61e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	8.9e-07	4.6e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—NRAS—ovarian cancer	8.9e-07	4.6e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—VEGFA—ovarian cancer	8.88e-07	4.59e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MAPK1—ovarian cancer	8.87e-07	4.58e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—EGFR—ovarian cancer	8.87e-07	4.58e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	8.86e-07	4.58e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—KRAS—ovarian cancer	8.85e-07	4.57e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—HRAS—ovarian cancer	8.83e-07	4.56e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—IL6—ovarian cancer	8.82e-07	4.55e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TP53—ovarian cancer	8.81e-07	4.55e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—STAT3—ovarian cancer	8.79e-07	4.54e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—AKT1—ovarian cancer	8.79e-07	4.54e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—AKT1—ovarian cancer	8.79e-07	4.54e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—MAPK1—ovarian cancer	8.78e-07	4.54e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—EGFR—ovarian cancer	8.78e-07	4.54e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CXCL8—ovarian cancer	8.77e-07	4.53e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—NRAS—ovarian cancer	8.77e-07	4.53e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—IL6—ovarian cancer	8.77e-07	4.53e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—AKT1—ovarian cancer	8.76e-07	4.53e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—IL6—ovarian cancer	8.7e-07	4.5e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PIK3CD—ovarian cancer	8.7e-07	4.49e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—VEGFA—ovarian cancer	8.69e-07	4.49e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—KRAS—ovarian cancer	8.65e-07	4.47e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—PIK3CA—ovarian cancer	8.61e-07	4.45e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—STAT3—ovarian cancer	8.61e-07	4.45e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—NRAS—ovarian cancer	8.59e-07	4.44e-06	CbGpPWpGaD
Dasatinib—LYN—Immune System—AKT1—ovarian cancer	8.58e-07	4.43e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CDKN1B—ovarian cancer	8.57e-07	4.43e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—VEGFA—ovarian cancer	8.56e-07	4.42e-06	CbGpPWpGaD
Dasatinib—ABL1—Immune System—AKT1—ovarian cancer	8.54e-07	4.41e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—MAPK3—ovarian cancer	8.52e-07	4.4e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—FASN—ovarian cancer	8.51e-07	4.39e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—AKT1—ovarian cancer	8.48e-07	4.38e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—STAT3—ovarian cancer	8.48e-07	4.38e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—NRAS—ovarian cancer	8.46e-07	4.37e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—IL6—ovarian cancer	8.45e-07	4.37e-06	CbGpPWpGaD
Dasatinib—FYN—Immune System—AKT1—ovarian cancer	8.45e-07	4.36e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—HRAS—ovarian cancer	8.43e-07	4.35e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MAPK3—ovarian cancer	8.4e-07	4.34e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CASP3—ovarian cancer	8.4e-07	4.34e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—HRAS—ovarian cancer	8.4e-07	4.34e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IL2—ovarian cancer	8.39e-07	4.33e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—KRAS—ovarian cancer	8.38e-07	4.33e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—SLC5A5—ovarian cancer	8.37e-07	4.32e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—KRAS—ovarian cancer	8.3e-07	4.29e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—MYC—ovarian cancer	8.29e-07	4.28e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ABCB1—ovarian cancer	8.27e-07	4.27e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—VEGFA—ovarian cancer	8.24e-07	4.26e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MAPK3—ovarian cancer	8.23e-07	4.25e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CD—ovarian cancer	8.22e-07	4.24e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—CAV1—ovarian cancer	8.19e-07	4.23e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—ERBB2—ovarian cancer	8.19e-07	4.23e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CCND1—ovarian cancer	8.17e-07	4.22e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MYC—ovarian cancer	8.17e-07	4.22e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—STAT3—ovarian cancer	8.16e-07	4.22e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—NRAS—ovarian cancer	8.14e-07	4.21e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—VEGFA—ovarian cancer	8.14e-07	4.2e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—AKT1—ovarian cancer	8.13e-07	4.2e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—PIK3CA—ovarian cancer	8.13e-07	4.2e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—TYMS—ovarian cancer	8.12e-07	4.19e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—MAPK1—ovarian cancer	8.11e-07	4.19e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—EGFR—ovarian cancer	8.11e-07	4.19e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MAPK3—ovarian cancer	8.1e-07	4.18e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CTNNB1—ovarian cancer	8.1e-07	4.18e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—AKT1—ovarian cancer	8.09e-07	4.18e-06	CbGpPWpGaD
Dasatinib—MAPK14—Gene Expression—AKT1—ovarian cancer	8.09e-07	4.18e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MTOR—ovarian cancer	8.08e-07	4.18e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PIK3CB—ovarian cancer	8.08e-07	4.18e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—SLC2A1—ovarian cancer	8.08e-07	4.17e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—IL6—ovarian cancer	8.06e-07	4.17e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—STAT3—ovarian cancer	8.06e-07	4.16e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—NRAS—ovarian cancer	8.04e-07	4.15e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—IL6—ovarian cancer	8.04e-07	4.15e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—AKT1—ovarian cancer	8.03e-07	4.15e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MYC—ovarian cancer	8e-07	4.13e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MAPK1—ovarian cancer	7.99e-07	4.13e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—EGFR—ovarian cancer	7.99e-07	4.13e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—HRAS—ovarian cancer	7.97e-07	4.11e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—PIK3CA—ovarian cancer	7.95e-07	4.11e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MMP9—ovarian cancer	7.94e-07	4.1e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PTEN—ovarian cancer	7.89e-07	4.08e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MYC—ovarian cancer	7.88e-07	4.07e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TP53—ovarian cancer	7.87e-07	4.06e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MAPK1—ovarian cancer	7.83e-07	4.04e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—EGFR—ovarian cancer	7.82e-07	4.04e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—AKT1—ovarian cancer	7.8e-07	4.03e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MAPK3—ovarian cancer	7.8e-07	4.03e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CXCL8—ovarian cancer	7.77e-07	4.01e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CYP1B1—ovarian cancer	7.75e-07	4e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MAPK1—ovarian cancer	7.7e-07	3.98e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—EGFR—ovarian cancer	7.7e-07	3.98e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—PIK3CA—ovarian cancer	7.7e-07	3.98e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MAPK3—ovarian cancer	7.7e-07	3.98e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—KRAS—ovarian cancer	7.66e-07	3.96e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—IL6—ovarian cancer	7.62e-07	3.94e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—PIK3CA—ovarian cancer	7.62e-07	3.94e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CDKN1B—ovarian cancer	7.59e-07	3.92e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MYC—ovarian cancer	7.58e-07	3.92e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PIK3CB—ovarian cancer	7.58e-07	3.92e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—KRAS—ovarian cancer	7.55e-07	3.9e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—HRAS—ovarian cancer	7.53e-07	3.89e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MYC—ovarian cancer	7.49e-07	3.87e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CG—ovarian cancer	7.46e-07	3.86e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TP53—ovarian cancer	7.45e-07	3.85e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—AKT1—ovarian cancer	7.44e-07	3.84e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CASP3—ovarian cancer	7.44e-07	3.84e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IL2—ovarian cancer	7.42e-07	3.84e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MAPK1—ovarian cancer	7.42e-07	3.83e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—EGFR—ovarian cancer	7.42e-07	3.83e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—AKT1—ovarian cancer	7.41e-07	3.83e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—KRAS—ovarian cancer	7.39e-07	3.82e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—HRAS—ovarian cancer	7.35e-07	3.8e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MAPK1—ovarian cancer	7.32e-07	3.78e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—EGFR—ovarian cancer	7.32e-07	3.78e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—KRAS—ovarian cancer	7.28e-07	3.76e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CCND1—ovarian cancer	7.24e-07	3.74e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—IL6—ovarian cancer	7.2e-07	3.72e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CTNNB1—ovarian cancer	7.17e-07	3.7e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CB—ovarian cancer	7.16e-07	3.7e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—VEGFA—ovarian cancer	7.13e-07	3.68e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—HRAS—ovarian cancer	7.12e-07	3.68e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—PIK3CA—ovarian cancer	7.09e-07	3.66e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—STAT3—ovarian cancer	7.06e-07	3.65e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—HRAS—ovarian cancer	7.05e-07	3.64e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—NRAS—ovarian cancer	7.04e-07	3.64e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—IL6—ovarian cancer	7.04e-07	3.64e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—PIK3CA—ovarian cancer	7.04e-07	3.64e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—AKT1—ovarian cancer	7.03e-07	3.63e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MMP9—ovarian cancer	7.03e-07	3.63e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—KRAS—ovarian cancer	7.01e-07	3.62e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PTEN—ovarian cancer	6.99e-07	3.61e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—PIK3CA—ovarian cancer	6.94e-07	3.58e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—KRAS—ovarian cancer	6.92e-07	3.57e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	6.87e-07	3.55e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—IL6—ovarian cancer	6.82e-07	3.52e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—PIK3CA—ovarian cancer	6.79e-07	3.51e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—IL6—ovarian cancer	6.75e-07	3.49e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MAPK3—ovarian cancer	6.74e-07	3.48e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TP53—ovarian cancer	6.71e-07	3.47e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—PIK3CA—ovarian cancer	6.69e-07	3.45e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—AKT1—ovarian cancer	6.64e-07	3.43e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TP53—ovarian cancer	6.57e-07	3.39e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CD—ovarian cancer	6.56e-07	3.39e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MYC—ovarian cancer	6.56e-07	3.39e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PTEN—ovarian cancer	6.55e-07	3.38e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CAV1—ovarian cancer	6.54e-07	3.38e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—HRAS—ovarian cancer	6.51e-07	3.36e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—AKT1—ovarian cancer	6.49e-07	3.35e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TP53—ovarian cancer	6.47e-07	3.34e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PIK3CA—ovarian cancer	6.45e-07	3.33e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—PIK3CA—ovarian cancer	6.44e-07	3.33e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—HRAS—ovarian cancer	6.42e-07	3.32e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MAPK1—ovarian cancer	6.41e-07	3.31e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—EGFR—ovarian cancer	6.41e-07	3.31e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ABCB1—ovarian cancer	6.38e-07	3.3e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—PIK3CA—ovarian cancer	6.36e-07	3.28e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—VEGFA—ovarian cancer	6.31e-07	3.26e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—AKT1—ovarian cancer	6.29e-07	3.25e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—HRAS—ovarian cancer	6.28e-07	3.25e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—TYMS—ovarian cancer	6.27e-07	3.24e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	6.25e-07	3.23e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—STAT3—ovarian cancer	6.25e-07	3.23e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—NRAS—ovarian cancer	6.23e-07	3.22e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—IL6—ovarian cancer	6.23e-07	3.22e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TP53—ovarian cancer	6.23e-07	3.22e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—AKT1—ovarian cancer	6.23e-07	3.22e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PTEN—ovarian cancer	6.19e-07	3.2e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—HRAS—ovarian cancer	6.19e-07	3.2e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TP53—ovarian cancer	6.15e-07	3.18e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—IL6—ovarian cancer	6.14e-07	3.17e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—KRAS—ovarian cancer	6.06e-07	3.13e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—IL6—ovarian cancer	6.01e-07	3.11e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MAPK3—ovarian cancer	5.97e-07	3.08e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CG—ovarian cancer	5.96e-07	3.08e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—HRAS—ovarian cancer	5.96e-07	3.08e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—IL6—ovarian cancer	5.92e-07	3.06e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—HRAS—ovarian cancer	5.88e-07	3.04e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MYC—ovarian cancer	5.8e-07	3e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—AKT1—ovarian cancer	5.79e-07	2.99e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—AKT1—ovarian cancer	5.75e-07	2.97e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CB—ovarian cancer	5.72e-07	2.95e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—IL6—ovarian cancer	5.7e-07	2.94e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MAPK1—ovarian cancer	5.68e-07	2.93e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—EGFR—ovarian cancer	5.68e-07	2.93e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—AKT1—ovarian cancer	5.67e-07	2.93e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IL6—ovarian cancer	5.63e-07	2.91e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PIK3CA—ovarian cancer	5.57e-07	2.88e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—AKT1—ovarian cancer	5.55e-07	2.87e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—AKT1—ovarian cancer	5.46e-07	2.82e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TP53—ovarian cancer	5.39e-07	2.78e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—KRAS—ovarian cancer	5.36e-07	2.77e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—AKT1—ovarian cancer	5.27e-07	2.72e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—AKT1—ovarian cancer	5.26e-07	2.72e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CD—ovarian cancer	5.24e-07	2.71e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—AKT1—ovarian cancer	5.19e-07	2.68e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—HRAS—ovarian cancer	5.15e-07	2.66e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CAV1—ovarian cancer	5.05e-07	2.61e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PTEN—ovarian cancer	4.94e-07	2.55e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IL6—ovarian cancer	4.93e-07	2.55e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PIK3CA—ovarian cancer	4.93e-07	2.55e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TP53—ovarian cancer	4.77e-07	2.46e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PIK3CA—ovarian cancer	4.62e-07	2.39e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CG—ovarian cancer	4.6e-07	2.38e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CB—ovarian cancer	4.57e-07	2.36e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—HRAS—ovarian cancer	4.56e-07	2.36e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—AKT1—ovarian cancer	4.55e-07	2.35e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CA—ovarian cancer	4.37e-07	2.26e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IL6—ovarian cancer	4.36e-07	2.25e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CD—ovarian cancer	4.04e-07	2.09e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—AKT1—ovarian cancer	4.03e-07	2.08e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PTEN—ovarian cancer	3.95e-07	2.04e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—AKT1—ovarian cancer	3.77e-07	1.95e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—AKT1—ovarian cancer	3.57e-07	1.84e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CB—ovarian cancer	3.52e-07	1.82e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CA—ovarian cancer	3.49e-07	1.8e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PTEN—ovarian cancer	3.05e-07	1.57e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—AKT1—ovarian cancer	2.85e-07	1.47e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CA—ovarian cancer	2.78e-07	1.44e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—AKT1—ovarian cancer	2.27e-07	1.17e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CA—ovarian cancer	2.15e-07	1.11e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—AKT1—ovarian cancer	1.75e-07	9.07e-07	CbGpPWpGaD
